Woodline Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

Woodline Partners’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-426,172	Closed	-$1.73M	–	619
2023 Q1	$1.73M	Hold	426,172	–	–	0.02%	432
2022 Q4	$2.3M	Sell	426,172 -5,986	-1%	-$40.2K	0.03%	458
2022 Q3	$4.33M	Buy	432,158 +5,988	+1%	+$34.3K	0.06%	328
2022 Q2	$2M	Sell	426,170 -75,066	-15%	-$282K	0.03%	422
2022 Q1	$1.96M	Buy	501,236 +20,555	+4%	+$112K	0.03%	385
2021 Q4	$3.25M	Buy	480,681 +11,887	+3%	+$131K	0.05%	346
2021 Q3	$6.97M	Buy	+468,794	New	+$7.8M	0.11%	213

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners's ABOS Position: Q2 2023 in Review

Woodline Partners sold out of Acumen Pharmaceuticals (ABOS) in Q2 2023, closing a stake of 426,172 shares — an estimated $1.73M sold.

Woodline Partners first reported a position in ABOS in Q3 2021 and held it in 7 quarters. The position peaked at $6.97M in Q3 2021. 53 funds tracked by Wall St. Rank hold ABOS as of Q2 2023.

Woodline Partners reported no remaining Acumen Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Woodline Partners sold 426,172 Acumen Pharmaceuticals shares in Q2 2023, an estimated $1.73M.
Woodline Partners first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Woodline Partners's Acumen Pharmaceuticals position peaked at $6.97M in Q3 2021.
53 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2023.

Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.